FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution

Culture change, not congressional action is needed advance this step toward faster drug development, FDA’s drug leader tells Energy & Commerce Committee.

Center for Drug Evaluation and Research Director Janet Woodcock put clinical trial networks on the top of her list of what could be done to speed the development of new drugs at a May 6 congressional meeting on how to modernize and accelerate biomedical innovation – and it shouldn’t require legislation to spur the change, she noted.

“If you step back and look at the whole ecosystem I think there are some major barriers that academics and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Capricor Gets Complete Response For DMD Cell Therapy: Unconvincing Data Or New Attitude At FDA?

 
• By 

Seven weeks before its action date and a month after an advisory committee was hastily cancelled, Capricor gets a CRL for its cell therapy deramiocel in DMD-related cardiomyopathy citing efficacy and manufacturing concerns. It has a Phase III study nearing readout, though.

ANDA User Fees: Complex Generics, Transparency, Communications Are Early Negotiation Targets

 
• By 

Teva seeks a dedicated development program and first-cycle approval metrics for complex generics. Role of artificial intelligence in the generic drug review process is a talking point for both agency and industry at reauthorization kickoff meeting.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.